<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296229</url>
  </required_header>
  <id_info>
    <org_study_id>13-001427</org_study_id>
    <secondary_id>NCI-2014-02183</secondary_id>
    <secondary_id>JCCCID410</secondary_id>
    <secondary_id>13-001427</secondary_id>
    <nct_id>NCT02296229</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer</brief_title>
  <official_title>Study of Stereotactic Body Radiotherapy (SBRT) for High-Risk Localized Prostrate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies stereotactic body radiation therapy in treating patients with&#xD;
      high-risk prostate cancer that has not spread to nearby lymph nodes or to other parts of the&#xD;
      body. Stereotactic body radiation therapy is a specialized radiation therapy that delivers a&#xD;
      single, high dose of radiation directly to the tumor and may kill more tumor cells and cause&#xD;
      less damage to normal tissue. Studying quality of life in patients undergoing stereotactic&#xD;
      body radiation therapy may help identify the long-term effects of treatment on patients with&#xD;
      prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To establish the efficacy of stereotactic body radiation therapy (SBRT) in patients with&#xD;
      high-risk localized prostate cancer compared to historical data from clinical trials.&#xD;
&#xD;
      II. To establish the safety with physician-reported outcomes after SBRT in patients with high&#xD;
      risk localized prostate cancer.&#xD;
&#xD;
      III. To establish the quality of life with patient-reported validated questionnaires after&#xD;
      SBRT in patients with high risk localized prostate cancer.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo SBRT daily or every other day for a total of 5 fraction not exceeding 14&#xD;
      consecutive days. Patients may also receive androgen deprivation therapy for up to 9 months&#xD;
      at the discretion of the treating physician.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 4 months for 1 year,&#xD;
      every 6 months for 5 years, and then every 12 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 27, 2014</start_date>
  <completion_date type="Anticipated">January 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 27, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical progression free survival</measure>
    <time_frame>At 3 years</time_frame>
    <description>Biochemical progression is defined as rising PSA profile of &gt; 2 ng/mL above post-SBRT nadir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical progression free survival</measure>
    <time_frame>At 5 years</time_frame>
    <description>Biochemical progression is defined as rising PSA profile of &gt; 2 ng/mL above post-SBRT nadir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of patient-reported genitourinary (GU) and gastrointestinal (GI) toxicity based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4</measure>
    <time_frame>At 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of patient-reported GU and GI toxicity based on the CTCAE version 4</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in health related quality of life based on Expanded Prostate Cancer Index Composite questionnaire</measure>
    <time_frame>Baseline to up to 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Stage III Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SBRT daily or every other day for a total of 5 fraction not exceeding 14 consecutive days. Patients may also receive androgen deprivation therapy for up to 9 months at the discretion of the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy</intervention_name>
    <description>Undergo SBRT</description>
    <arm_group_label>Treatment (SBRT)</arm_group_label>
    <other_name>SBRT</other_name>
    <other_name>stereotactic radiation therapy</other_name>
    <other_name>stereotactic radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (SBRT)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (SBRT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>androgen deprivation therapy</intervention_name>
    <description>up to 9 months at the discretion of the treating physician</description>
    <arm_group_label>Treatment (SBRT)</arm_group_label>
    <other_name>androgen suppression therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed primary non-metastatic adenocarcinoma of the prostate&#xD;
&#xD;
          -  Risk-group classification into the Dâ€™Amico or National Comprehensive Cancer Network&#xD;
             (NCCN) â€˜high-riskâ€™ group, as defined by the presence of any one of the following&#xD;
             high-risk factors:&#xD;
&#xD;
               -  Pre-biopsy prostate-specific antigen (PSA) &gt;= 20&#xD;
&#xD;
               -  Biopsy Gleason score 8-10&#xD;
&#xD;
               -  Clinical stage T3&#xD;
&#xD;
          -  No pelvic nodal metastases (based on computed tomography [CT] or magnetic resonance&#xD;
             imaging [MRI] findings)&#xD;
&#xD;
          -  No distant metastases, based upon:&#xD;
&#xD;
               -  CT scan or MRI of the pelvis within 120 days prior to registration&#xD;
&#xD;
               -  Bone scan within 120 days prior to registration; if the bone scan is suspicious,&#xD;
                  a plain x-ray and/or MRI must be obtained to rule out metastasis&#xD;
&#xD;
          -  Karnofsky performance status (KPS) &gt;= 70&#xD;
&#xD;
          -  Ability to understand, and willingness to sign, the written informed consent&#xD;
&#xD;
          -  Patient will have opted for SBRT among definitive treatment choices&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any evidence of distant metastases&#xD;
&#xD;
          -  Hormonal therapy (luteinizing hormone-releasing hormone [LHRH] agonist or oral&#xD;
             anti-androgen) exceeding 4 months prior to registration&#xD;
&#xD;
          -  Prior cryosurgery, high intensity focused ultrasound (HIFU) or brachytherapy of the&#xD;
             prostate&#xD;
&#xD;
          -  Prior pelvic radiotherapy&#xD;
&#xD;
          -  History of Crohnâ€™s disease or Ulcerative colitis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amar Kishan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

